Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amnesia D000647 12 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Anthrax D000881 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Asthma D001249 52 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Birth Weight D001724 23 associated lipids
Blister D001768 16 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Body Weight D001835 333 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Brain Injuries D001930 4 associated lipids
Bronchial Diseases D001982 3 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Burns D002056 34 associated lipids
Burns, Inhalation D002059 4 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cholecystitis D002764 8 associated lipids
Cholestasis D002779 23 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Cluster Headache D003027 4 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Colonic Diseases D003108 5 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Conjunctivitis D003231 7 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Contracture D003286 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Death, Sudden D003645 12 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyslexia D004410 3 associated lipids
Ear Diseases D004427 7 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Gastritis D005756 27 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Heart Arrest D006323 13 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Injuries D006335 6 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemolysis D006461 131 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Rhee CK et al. Effect of platelet activating factor and its antagonist on the mucociliary clearance of the eustachian tube in guinea pigs. 1999 Ann. Otol. Rhinol. Laryngol. pmid:10335705
Diven WF et al. Expression of acute otitis media after receptor blockade of platelet activating factor, thromboxane, and leukotrienes in the chinchilla. 1998 Ann. Otol. Rhinol. Laryngol. pmid:9525240
Jeon SY et al. Rat model of platelet-activating factor-induced rhinosinusitis. 2005 Ann. Otol. Rhinol. Laryngol. pmid:15966528
Ganbo T et al. Effects of platelet activating factor on mucociliary clearance of the eustachian tube. 1996 Ann. Otol. Rhinol. Laryngol. pmid:8659935
Lin J et al. Effect of lipoxygenase inhibition on mucous glycoprotein secretion from chinchilla middle ear epithelial cells in vitro. 1996 Ann. Otol. Rhinol. Laryngol. pmid:8916869
Rhee CK et al. Experimental otitis media with effusion induced by platelet activating factor. 1993 Ann. Otol. Rhinol. Laryngol. pmid:8352483
Jung TT et al. Effect of platelet activating factor with and without receptor antagonist (WEB2170) on morphology of isolated cochlear outer hair cells. 2004 Ann. Otol. Rhinol. Laryngol. pmid:14994775
Price JE et al. In vitro platelet aggregability studies: lack of evidence for platelet hyperactivity in systemic sclerosis. 1991 Ann. Rheum. Dis. pmid:1888199
Hilliquin P et al. Presence of paf-acether in rheumatic diseases. 1992 Ann. Rheum. Dis. pmid:1540032
Herrero-Beaumont G and Egido J PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. 1997 Ann. Rheum. Dis. pmid:9165991
Hilliquin P et al. Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730. 1995 Ann. Rheum. Dis. pmid:7702404
Eggleton P et al. Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis. 1995 Ann. Rheum. Dis. pmid:7492242
Kaminski DL et al. The role of prostanoids in the production of acute acalculous cholecystitis by platelet-activating factor. 1990 Ann. Surg. pmid:2171443
Fletcher JR et al. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. 1990 Ann. Surg. pmid:2178565
Yamakawa Y et al. Interaction of platelet activating factor, reactive oxygen species generated by xanthine oxidase, and leukocytes in the generation of hepatic injury after shock/resuscitation. 2000 Ann. Surg. pmid:10714632
Heinrich S et al. Evidence-based treatment of acute pancreatitis: a look at established paradigms. 2006 Ann. Surg. pmid:16432347
Spitzer AL et al. Applying Ockham's razor to pancreatitis prognostication: a four-variable predictive model. 2006 Ann. Surg. pmid:16495704
Ontell SJ et al. Pharmacologic modulation of experimental postischemic hepatic function. 1989 Ann. Surg. pmid:2916864
Makowka L et al. Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. 1987 Ann. Surg. pmid:3310931
Unno N et al. Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. 2002 Ann. Surg. pmid:11807372
Nathan N and Denizot Y Platelet-activating factor antagonist and cardiopulmonary bypass. 1995 Ann. Thorac. Surg. pmid:7677525
Zehr KJ et al. Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. 1995 Ann. Thorac. Surg. pmid:7847945
Taggart DP Effects of a platelet-activating factor antagonist on lung injury and ventilation after cardiac operation. 2001 Ann. Thorac. Surg. pmid:11216754
Qayumi AK et al. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury. 1998 Ann. Thorac. Surg. pmid:9647083
Kim JD et al. Platelet activating factor acetylhydrolase decreases lung reperfusion injury. 2000 Ann. Thorac. Surg. pmid:10969656
Corcoran PC et al. Reduction of conjugated dienes in lung transplantation: effect of BN 52021. 1993 Ann. Thorac. Surg. pmid:8267425
Qayumi AK et al. Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation. 1991 Ann. Thorac. Surg. pmid:1929620
Nathan N and Denizot Y Tumor necrosis factor and platelet-activating factor during cardiopulmonary bypass. 1993 Ann. Thorac. Surg. pmid:8494455
Zhang J et al. Strategies of myocardial protection for operation in chronic model of cyanotic heart disease. 1998 Ann. Thorac. Surg. pmid:9875743
Hanahan DJ Platelet activating factor: a biologically active phosphoglyceride. 1986 Annu. Rev. Biochem. pmid:3017194
Prescott SM et al. Platelet-activating factor and related lipid mediators. 2000 Annu. Rev. Biochem. pmid:10966465
Larsen GL and Henson PM Mediators of inflammation. 1983 Annu. Rev. Immunol. pmid:6399978
Parker CW Lipid mediators produced through the lipoxygenase pathway. 1987 Annu. Rev. Immunol. pmid:3036183
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Saunders RN and Handley DA Platelet-activating factor antagonists. 1987 Annu. Rev. Pharmacol. Toxicol. pmid:3555317
Feuerstein G and Hallenbeck JM Prostaglandins, leukotrienes, and platelet-activating factor in shock. 1987 Annu. Rev. Pharmacol. Toxicol. pmid:3034139
Vanhoutte PM et al. Modulation of vascular smooth muscle contraction by the endothelium. 1986 Annu. Rev. Physiol. pmid:2871807
Semini G et al. Glycosidated phospholipids - a promising group of anti-tumour lipids. 2014 Anticancer Agents Med Chem pmid:24628240
Zimmermann A and Keller H Shape changes and chemokinesis of Walker carcinosarcoma cells: effects of protein kinase inhibitors (HA-1004, polymyxin B, sangivamycin and tamoxifen) and an inhibitor of diacylglycerol kinase (R 59022). 1993 Mar-Apr Anticancer Res. pmid:8390801
Adamson LM et al. Release of anti-PAF activity from PAF-binding human ovarian cancer cells in culture. 1992 Mar-Apr Anticancer Res. pmid:1580546
Berdel WE et al. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro. 1987 Nov-Dec Anticancer Res. pmid:3442414
Torley LW et al. Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. 1992 Antimicrob. Agents Chemother. pmid:1416889
Nunn B et al. Effect of temocillin and moxalactam on platelet responsiveness and bleeding time in normal volunteers. 1985 Antimicrob. Agents Chemother. pmid:4015075
Lang F et al. Mechanisms and significance of eryptosis. 2006 Jul-Aug Antioxid. Redox Signal. pmid:16910766
Cao YZ et al. Selenium modulates 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) biosynthesis in bovine aortic endothelial cells. 2001 Antioxid. Redox Signal. pmid:11813988
Kamaladasa A et al. Lipopolysaccharide acts synergistically with the dengue virus to induce monocyte production of platelet activating factor and other inflammatory mediators. 2016 Antiviral Res. pmid:27476044
Chamogeorgakis TP et al. Effect of N-acetyl-L-cysteine on lung ischaemia reperfusion injury in a porcine experimental model. 2008 Jan-Feb ANZ J Surg pmid:18199211
Steel HC et al. Platelet-activating factor and lyso-PAF possess direct antimicrobial properties in vitro. 2002 APMIS pmid:12064871
Ginesta MM et al. Modulation of the pathology of late xenograft rejection by PAF-antagonist UR-12670 in the hamster-to-rat liver xenotransplant model. 2003 APMIS pmid:12752216
Marrakchi N et al. [Biochemical and pharmacologic properties of platelet aggregants and platelet antiaggregants of viper venoms in Tunisia]. 1994 Jul-Oct Arch Inst Pasteur Tunis pmid:8801850
Subissi A et al. Octylonium bromide, an antagonist of platelet-activating factor. 1989 Nov-Dec Arch Int Pharmacodyn Ther pmid:2636821
Yamada T et al. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. 1990 Nov-Dec Arch Int Pharmacodyn Ther pmid:2099131
Damas J et al. Inhibition by WEB 2086, a PAG-acether antagonist of oedema and peritonitis induced by zymosan in rats. 1990 Jul-Aug Arch Int Pharmacodyn Ther pmid:2076045
Damas J and Prunescu P Presence of immunoreactive platelet-activating factor in peritoneal exudate induced by zymosan in rats. 1993 Mar-Apr Arch Int Pharmacodyn Ther pmid:8215712
Hemmendinger S et al. [Physiology of the interactions of blood and the blood vessel wall. Role of pharmacologically active lipids]. 1985 Arch Mal Coeur Vaiss pmid:3938941
Jambou D et al. [Mediators of the vascular endothelium as markers of myocardial ischemia and reperfusion]. 1993 Arch Mal Coeur Vaiss pmid:8304814
Gateau O [Role of PAF-acether (platelet activating factor) in cardio-vascular pathology]. 1987 Arch Mal Coeur Vaiss pmid:3117010
Partrick DA et al. Maximal human neutrophil priming for superoxide production and elastase release requires p38 mitogen-activated protein kinase activation. 2000 Arch Surg pmid:10668885
Kelly GL and Eiseman B Development of a new vascular prosthetic: lessons learned. 1982 Arch Surg pmid:7125901
Arbabi S et al. Priming interleukin 8 production: role of platelet-activating factor and p38. 1999 Arch Surg pmid:10593333
Emil S et al. Inhaled nitric oxide prevents experimental platelet activating factor-induced shock. 1996 Arch Surg pmid:8712910
Biffl WL et al. Interleukin-6 potentiates neutrophil priming with platelet-activating factor. 1994 Arch Surg pmid:7979944
Lo CJ et al. Endotoxin-induced macrophage gene expression depends on platelet-activating factor. 1997 Arch Surg pmid:9403541
Fletcher JR Eicosanoids. Critical agents in the physiological process and cellular injury. 1993 Arch Surg pmid:8239981
Thompson WA et al. The metabolic effects of platelet-activating factor antagonism in endotoxemic man. 1994 Arch Surg pmid:8279943
Vadnais ML et al. Current concepts of molecular events during bovine and porcine spermatozoa capacitation. 2007 May-Jun Arch. Androl. pmid:17612869
Jones RE Synthesis of ether lipids and phosphatidylethanolamine by ejaculated human spermatozoa. 1997 May-Jun Arch. Androl. pmid:9140614
Ohtsuka T et al. Synergism between platelet-activating factor and diacylglycerol in the induction of superoxide anion production in guinea pig polymorphonuclear leukocytes. 1990 Arch. Biochem. Biophys. pmid:2159756
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
Lee T et al. Differential regulation of three catalytic activities of platelet-activating factor (PAF)-dependent transacetylase. 2001 Arch. Biochem. Biophys. pmid:11368182
Furukawa M et al. Metabolic fate of platelet-activating factor in the rat enterocyte: the role of a specific lysophospholipase D. 1995 Arch. Biochem. Biophys. pmid:7771795
Lekka M et al. Isolation of a phospholipid inhibitor of platelet activating factor-induced activity from perfused rat liver: identification as phosphatidylglycerol. 1993 Arch. Biochem. Biophys. pmid:8489242
Shukla SD Platelet activating factor-stimulated formation of inositol triphosphate in platelets and its regulation by various agents including Ca2+, indomethacin, CV-3988, and forskolin. 1985 Arch. Biochem. Biophys. pmid:3875314
Sugatani J and Hanahan DJ Characterization of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC)-induced protein phosphorylation in rabbit platelets: inhibitory effects of AGEPC analogs. 1986 Arch. Biochem. Biophys. pmid:3754710
Kimoto M et al. Dual effects of oleic acid on Ca2+ mobilization and protein phosphorylation in human platelets in presence or absence of platelet activating factor. 1992 Arch. Biochem. Biophys. pmid:1384432
Kajiyama Y et al. Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets. 1989 Arch. Biochem. Biophys. pmid:2505676
Argyroudi-Akoyunoglou JH and Vakirtzi-Lemonias C Low-temperature fluorescence emission changes in thylakoids induced by acetyl glyceryl ether phosphorylcholine (AGEPC). 1987 Arch. Biochem. Biophys. pmid:3813566
Zhou W and Olson MS A mechanism for phorbol ester-mediated regulation of the PAF receptor in human neutrophils. 1994 Arch. Biochem. Biophys. pmid:8053680
Satouchi K et al. Influence of alkyl ether chain length of acetyl glyceryl ether phosphorylcholine and its ethanolamine analog on biological activity toward rabbit platelets. 1981 Arch. Biochem. Biophys. pmid:7305392
Zhou W et al. Impaired surface expression of PAF receptors on human neutrophils is dependent upon cell activation. 1994 Arch. Biochem. Biophys. pmid:8109973
Heinsohn C et al. The effect of bovine serum albumin on the synthesis of prostaglandin and incorporation of [3H]acetate into platelet-activating factor. 1987 Arch. Biochem. Biophys. pmid:3662526
Tokumura A et al. Alkylacetylglycerophosphocholine effects on the metabolism of phospholipids in rabbit platelets: effects of extracellular Ca2+ and prostacyclin. 1986 Arch. Biochem. Biophys. pmid:3013094
Satouchi K et al. Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor. 1984 Arch. Biochem. Biophys. pmid:6486825
Homma H et al. Some unique features of the metabolic conversion of platelet-activating factor (AGEPC) to alkyl acyl PC by washed rabbit platelets. 1987 Arch. Biochem. Biophys. pmid:3101596
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Svetlov SI et al. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. 1996 Arch. Biochem. Biophys. pmid:8615681
Argyroudi-Akoyunoglou JH and Vakirtzi-Lemonias C Enhancement of chlorophyll a fluorescence yield, low-temperature F685/F730 fluorescence emission ratio, and electron transport rate by ether phospholipids (platelet activating factor and analogs) in isolated chloroplasts. 1989 Arch. Biochem. Biophys. pmid:2817899
Ban C et al. Metabolism of platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human fetal membranes and decidua vera. 1986 Arch. Biochem. Biophys. pmid:3963833
Ludwig JC et al. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. 1985 Arch. Biochem. Biophys. pmid:4037794
Kumar R et al. Occurrence of platelet-activating factor in rabbit spermatozoa. 1988 Arch. Biochem. Biophys. pmid:3341753
Huo YN et al. A preferential inhibition by Zn2+ on platelet activating factor- and thrombin-induced serotonin secretion from washed rabbit platelets. 1988 Arch. Biochem. Biophys. pmid:3341767
Nunez D et al. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets. 1989 Arch. Biochem. Biophys. pmid:2502069
Lee TC et al. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in rabbit platelets: possible involvement of the lipoxygenase pathway. 1983 Arch. Biochem. Biophys. pmid:6407399
Homma H and Hanahan DJ Attenuation of platelet activating factor (PAF)-induced stimulation of rabbit platelet GTPase by phorbol ester, dibutyryl cAMP, and desensitization: concomitant effects on PAF receptor binding characteristics. 1988 Arch. Biochem. Biophys. pmid:2833174
Ihara Y et al. Hormonal regulation of platelet-activating factor-acetyltransferase activity in rat tissues. 1993 Arch. Biochem. Biophys. pmid:8346925
Sanwick JM et al. Human spermatozoa produce C16-platelet-activating factor. 1992 Arch. Biochem. Biophys. pmid:1575513
Hwang SB Specific receptor sites for platelet activating factor on rat liver plasma membranes. 1987 Arch. Biochem. Biophys. pmid:2821908
Browne PC et al. Kinetics of the formation of thrombin-thrombospondin complexes: involvement of a 77-kDa intermediate. 1988 Arch. Biochem. Biophys. pmid:2844122
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Sugiura T et al. Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor. 1994 Arch. Biochem. Biophys. pmid:8203898